Research programme: anti-CD55 monoclonal antibodies - Viragen

Drug Profile

Research programme: anti-CD55 monoclonal antibodies - Viragen

Alternative Names: CD55 cancer vaccine - Viragen Scotland; CD55 vaccine - Viragen Scotland; VG 102

Latest Information Update: 04 Feb 2008

Price : $50

At a glance

  • Originator Cancer Research Technology; University of Nottingham
  • Developer Viragen Scotland
  • Class Monoclonal antibodies
  • Mechanism of Action CD55 antigen inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 06 Jun 2007 This programme is still in active development
  • 09 May 2005 The anti-CD55 antibody has been licensed to Viragen worldwide
  • 21 Mar 2005 Preclinical data from a media release have been added to the Cancer pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top